The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Reduction of Hypothalamic Vasopressinergic Hyperdrive Contributes to Clinically Relevant Behavioral and Neuroendocrine Effects of Chronic Paroxetine Treatment in a Psychopathological Rat Model
Open accessAbstract
The neuroendocrine and behavioral effects of chronic paroxetine treatment were investigated in two rat lines selectively bred for high anxiety-related behavior (HAB) or low anxiety-related behavior (LAB) emotionality. In addition to a characteristic behavioral phenotype with markedly passive stress-coping strategies, HAB rats show a hypothalamic vasopressinergic hyperdrive that is causally related to hypothalamic-pituitary-adrenocortical dysregulation as demonstrated in the combined dexamethasone (DEX)/corticotropin-releasing hormone (CRH) test. A total of 8 weeks of chronic paroxetine treatment induced a more active coping strategy in the forced swim test in HAB rats only. In contrast, paroxetine-treated LAB rats did not change their swimming behavior. To investigate the neuroendocrine alterations linked to these behavioral changes, a combined DEX/CRH test was performed. In HAB rats, the paroxetine-induced behavioral changes towards more active coping strategies were accompanied by a normalization of the CRH-stimulated increase in corticotropin (ACTH) and corticosterone secretion. Concomitantly, the hypothalamic vasopressinergic hyperdrive was found to be reduced in HAB but not LAB rats, as indicated by a decrease in vasopressin mRNA expression, whereas vasopressin 1a receptor binding was unaffected. These findings provide the first evidence that the vasopressinergic system is likely to be critically involved in the behavioral and neuroendocrine effects of antidepressant drugs. This novel mechanism of action of paroxetine on vasopressin gene regulation renders vasopressinergic neuronal circuits a promising target for the development of more causal antidepressant treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin
Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965
Purba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433
Vasopressin and oxytocin receptors in the central nervous system
Tribollet, E., & Barberis, C. (1996) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v10.i1.60 · Cited by 399 · cited 2×
“The V1a receptor, which is highly expressed in the rat lateral septum, thalamic nuclei, and the amygdalostriatal transition area (Barberis and Tribollet, 1996), is well known to play a role in a variety of behavioral effects such as the modulation of emotionality and stress coping (Landgraf et al, 1998).”
BackgroundZobel, A. W., Nickel, T., Sonntag, A., Uhr, M., Holsboer, F., & Ising, M. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00013-9 · Cited by 354
Self-citationPlasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression
van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.656 · Cited by 278
Neuropeptides and the evolution of social behavior
Insel, T. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00146-x · Cited by 264
von Bardeleben, U., & Holsboer, F. (1989) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1989.tb00150.x · Cited by 161
Self-citationClinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression
Nickel, T., Sonntag, A., Schill, J., Zobel, A. W., Ackl, N., Brunnauer, A., Murck, H., Ising, M., Yassouridis, A., Steiger, A., et al. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00008 · Cited by 152
Self-citationStout, S. C., Owens, M. J., & Nemeroff, C. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1085 · Cited by 117
Cited by
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Landgraf, R., & Neumann, I. D. (2004) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2004.05.001 · Cited by 1,059
Self-citationNeumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954
Self-citationThe Effects of Psychological Stress on Depression
Yang, L., Zhao, Y., Wang, Y., Liu, L., Zhang, X., Li, B., & Cui, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x1304150831150507 · Cited by 589
The stress system in depression and neurodegeneration: Focus on the human hypothalamus
Bao, A.-M., Meynen, G., & Swaab, D. F. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.04.005 · Cited by 548
Metadata
- Authors
- Keck, M. E., Welt, T., Müller, M. B., Uhr, M., Ohl, F., Wigger, A., Toschi, N., Holsboer, F., & Landgraf, R.
- Venue
- Neuropsychopharmacology
- Published
- 2002-07-25
- Volume
- 28
- Issue
- 2
- Pages
- 235-243
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2048146758
- Cited by
- 168
- References
- 10
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduction of Hypothalamic Vasopressinergic Hyperdrive Contributes to Clinically Relevant Behavioral and Neuroendocrine Effects of Chronic Paroxetine Treatment in a Psychopathological Rat Model. https://app.cochat.ai/papers/10.1038/sj.npp.1300040
- The paper
- Keck, M. E., Welt, T., Müller, M. B., Uhr, M., Ohl, F., Wigger, A., Toschi, N., Holsboer, F., & Landgraf, R. (2003). Reduction of Hypothalamic Vasopressinergic Hyperdrive Contributes to Clinically Relevant Behavioral and Neuroendocrine Effects of Chronic Paroxetine Treatment in a Psychopathological Rat Model. Neuropsychopharmacology. https://doi.org/10.1038/sj.npp.1300040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
